InVivoMAb anti-mouse NKG2A/C/E BE0321-R100mg from Bio X Cell

Description

Bio X Cell InVivoMAb anti-mouse NKG2A/C/E Monoclonal Antibody has the following reported applications: in vivo NKG2A blockade (see description), in vitro NKG2A blockade, Immunohistochemistry (frozen), Flow cytometry. It features greater than 95% purity, ultra-low endotoxin levels, and are preservative, stabilizer, and carrier protein-free

Product Specs
ItemInVivoMAb anti-mouse NKG2A/C/E
CompanyBio X Cell
Price Pricing Info Supplier Page View Company Product Page
Catalog NumberBE0321-R100mg
Quantity100 mg
Applicationsin vivo NKG2A blockade (see description), in vitro NKG2A blockade, Immunohistochemistry (frozen), Flow cytometry
ConcentrationLot specific,typically between 4-11 mg/ml
Conjugate/TagUnconjugated
ReactivityMouse
TargetNKG2A/C/E
IsotypeIgG2a, κ
Clone20D5
HostRat
Antibody TypePrimary Antibody
ImmunogenCHO transfected cells expressing the B6 allele of NKG2A and CD94
NCBI Full Gene Namekiller cell lectin-like receptor subfamily C, member 1, killer cell lectin-like receptor subfamily C, member 3, killer cell lectin-like receptor subfamily C, member 2
NCBI Gene AliasesKlrc2, CD159a, Nkg2e, NKG2C, NKG2B, NKG2A
ClonalityMonoclonal
Purity>95%, Determined by SDS-PAGE
FormatPBS, pH 7.0, Contains no stabilizers or preservatives
Research AreaCancer Biology, Immunology, Innate Immunity

Specifications/Features

Other available quantities: Available in 1, 5, 10, 25, 50, 100 mg and bulk sizes. Academic discount available.

Endotoxin: <2EU/mg (<0.002EU/µg), Determined by LAL gel clotting assay

Add to Compare List

Bio X Cell

39 Labombard Rd

Lebanon, NH 03766

United States

Phone: 1-866-787-3444

Email: customerservice@bxcell.com

Company Profile

Website: bioxcell.com

(1) Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK CellsCellDecember 13, 2018André P, Denis C, Soulas C, Bourbon-Caillet C, Lopez J, Arnoux T, Bléry M, Bonnafous C, Gauthier L, Morel A, et al.

(2) NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer VaccinesCellDecember 13, 2018van Montfoort N, Borst L, Korrer MJ, Sluijter M, Marijt KA, Santegoets SJ, van Ham VJ, Ehsan I, Charoentong P, André P, et al.

(3) Intratumoral hu14.18-IL-2 (IC) induces local and systemic antitumor effects that involve both activated T and NK cells as well as enhanced IC retentionJournal of immunology (Baltimore, Md. : 1950)September 1, 2012Yang RK, Kalogriopoulos NA, Rakhmilevich AL, Ranheim EA, Seo S, Kim K, Alderson KL, Gan J, Reisfeld RA, Gillies SD, et al.

(4) Recognition of the class Ib molecule Qa-1(b) by putative activating receptors CD94/NKG2C and CD94/NKG2E on mouse natural killer cellsThe Journal of experimental medicineDecember 20, 1999Vance RE, Jamieson AM, Raulet DH.

Be the First to Write a Review!